Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Vecabrutinib (SNS-062) Program Presentations

Download a presentation for more information.
Adobe® Reader®


SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase.
AACR Annual Meeting 2017
Washington, D.C., USA
April 3, 2017
Download (PDF,158KB)

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton’s Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects
58th ASH Annual Meeting & Exposition
San Diego, California
December 3, 2016
Download (PDF,315KB)

A Phase 1a Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton’s Tyrosine Kinase Inhibitor SNS-062 in Healthy Subjects: Preliminary Results.
ESH 2nd International Conference on New Concepts in B-Cell Malignancies
Estoril, Portugal
September, 10 2016
Download (PDF,606KB)

SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boston, MA
Sunday, November 8, 2015
Download (PDF,998KB)

Vecabrutinib (SNS-062) Program Publications

Download reprints of research and studies which have been submitted to scientific and medical journals.

Other Relevant Publications

Jennifer A. Woyach Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly, Arletta Lozanski, Nyla A. Heerema, Weiqiang Zhao, Joshua Coleman, Daniel Jones, Lynne Abruzzo, Amber Gordon, Rose Mantel, Lisa L. Smith, Samantha McWhorter,Melanie Davis, Tzyy-Jye Doong, Fan Ny,Margaret Lucas,Weihong Chase, Jeffrey A. Jones, Joseph M. Flynn, KamiMaddocks, Kerry Rogers, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Gerard Lozanski, Amy J. Johnson, and John C. Byrd BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13

Meixiao Long, Kyle Beckwith, Priscilla Do, Bethany L. Mundy, Amber Gordon, Amy M. Lehman, Kami J. Maddocks, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Farrukh Awan, Joseph A. Fraietta, Carl H. June, Marcela V. Maus, Jennifer A. Woyach, Michael A. Caligiuri, Amy J. Johnson, Natarajan Muthusamy, and John C. Byrd Ibrutinib treatment improves T cell number and function in CLL patients J Clin Invest. 2017;127(8):3052–3064. doi:10.1172/JCI89756.

Jennifer A. Woyach, M.D., Richard R. Furman, M.D., Ta-Ming Liu, M.S., Hatice Gulcin Ozer, Ph.D., Marc Zapatka, Ph.D., Amy S. Ruppert, M.A.S., Ling Xue, Ph.D., Daniel Hsieh-Hsin Li, Ph.D., Susanne M. Steggerda, Ph.D., Matthias Versele, Ph.D., Sandeep S. Dave, M.D., Jenny Zhang, B.S., Ayse Selen Yilmaz, M.S., Samantha M.Jaglowski, M.D., M.P.H., Kristie A. Blum, M.D., Arletta Lozanski, M.S., Gerard Lozanski, M.D., Danelle F.James, M.D.,Jacqueline C. Barrientos, M.D., Peter Lichter, Ph.D., Stephan Stilgenbauer, M.D.,JosephJ. Buggy, Ph.D., Betty Y. Chang, Ph.D., Amy J.Johnson, Ph.D., and John C. Byrd, M.D. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib N Engl J Med 2014; 370:2286-2294June 12, 2014DOI: 10.1056/NEJMoa1400029

Furman , Richard R. and Cheng , Shuhua and Lu , Pin and Setty , Menu and Perez , Alexendar R. and Guo , Ailin and Racchumi , Joelle and Xu , Guozhou and Wu , Hao and Ma , Jiao and Steggerda , Susanne M. and Coleman , Morton and Leslie , Christina and Wang , Y. Lynn Ibrutinib Resistance in Chronic Lymphocytic Leukemia N Engl J Med 2014; 370:2352-2354June 12, 2014DOI: 10.1056/NEJMc1402716